Real-world Observational Multi-center Study: Retrospective Analysis of Diagnostic and Treatment Patterns for Stage III–IV Melanoma in Ukraine from 2018 to 2020

Mariia Kukushkina; Dinara Ryspayeva; Natalia Lisovska; Yevhen Kryvonos; Vasyl  Skrypko; Iryna Sokur; Tetiana Tarasenko; Irina Burma; Yevhen Gotko; Nadiia Salo; Bernadette Poellinger; Hala Zreikat

doi:10.3889/oamjms.2024.11805

Authors

Mariia Kukushkina 1National Cancer Institute, Kyiv, 03022, Ukraine https://orcid.org/0000-0001-9197-9776
Dinara Ryspayeva LISOD - Israeli Oncological Hospital, Kyivska Oblast, 08700, Ukraine https://orcid.org/0000-0002-7483-6228
Natalia Lisovska LLC “Medical Center Named by Academician Yu. Spizhenko,” Kyivska Oblast, 08112, Ukraine https://orcid.org/0000-0001-6114-708X
Yevhen Kryvonos Lviv Oncological Regional Medical and Diagnostic Center, Lviv, 79000, Ukraine
Vasyl Skrypko Carpathian Clinical Oncology Center, Ivano-Frankivsk, 77458, Ukraine
Iryna Sokur Kherson Regional Oncological Dispensary, Kherson, 73000, Ukraine
Tetiana Tarasenko LLC “Medical Clinic “Innovacia,” Kyivska Oblast, 07352, Ukraine
Irina Burma Julis Medical Center, Zaporizhzhia, 69000, Ukraine
Yevhen Gotko Central City Clinical Hospital, Uzhgorod, 88017, Ukraine
Nadiia Salo MSD Kyiv, 03088, Ukraine https://orcid.org/0009-0004-3942-8669
Bernadette Poellinger MSD Munich, 81673, Germany https://orcid.org/0009-0008-3495-3930
Hala Zreikat MSD Amman, 11732, Jordan https://orcid.org/0009-0000-2864-6602

DOI:

https://doi.org/10.3889/oamjms.2024.11805

Keywords:

Melanoma, diagnosis, Chemotherapy, Immunotherapy, Targeted therapy

Abstract

BACKGROUND: Despite open-access sources with information about cancer patients (National Cancer Registry of Ukraine), there are considerable gaps about actual diagnostic methods and specific treatment patterns or any details on how different regimens are applied for melanoma treatment in Ukraine.

OBJECTIVES: This non-interventional, multicenter, retrospective medical chart review study aims to describe real-world therapeutic strategies and characterize the profile of patients with melanoma Stage III–IV in real-life clinical practice in Ukraine.

METHODS: Anonymized data were collected from medical records of 747 patients in 9 oncology centers in Ukraine - four private and five public. The data variables were retrieved, captured in electronic case report forms, and analyzed with descriptive statistical methods.

INCLUSION CRITERIA: Subjects were not enrolled unless they met all the following criteria: (1) Age >18 years at the time of being diagnosed with III–IV stage melanoma. (2) Morphologically (including cytology) confirmed diagnosis of III–IV stage melanoma. Sufficient available medical records for data abstraction to meet the objectives of the study, that is, the patient has been under the medical care of the participating site for the entirety of the patient observation period or the patient’s detailed historical data on their disease course, and clinical management are otherwise available at the participating site consent has been granted by the Institutional Review Board/Ethical Committee of the study site.

EXCLUSION CRITERIA: Subjects were not enrolled if they met any of the following criteria: (1) The patient has received treatment with anticancer systemic therapy for reasons other than melanoma. (2) Primary cancer other than melanoma. (3) The patient is participating (or was participating) in any investigational program/clinical trial with interventions outside of routine clinical practice. All the statistical tests were two sided and performed at a 0.05 significance level. p-values were rounded to three decimal places. p < 0.001 were reported as <0.001 in tables.

RESULTS: Most melanoma cases (95.05%) were diagnosed histologically, although information about the primary tumor’s characteristics and treatment are heterogeneous. Most individuals (51.05%) diagnosed with Stage III undergo surgical treatment without additional therapy. Chemotherapy constitutes the primary form of systemic therapy for Stages III and IV, accounting for 33.3% and 45.65%, respectively.

CONCLUSION: It is crucial to tackle the problems associated with diagnosing and treating melanoma in Ukraine. This involves creating a unified registry for melanoma patients, establishing uniform methods for staging and re-staging, and standardizing medical records. Nevertheless, the most critical issue is the absence of access to modern therapy, which should be addressed at the state level.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho ER. Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and Therapy. Australia: Exon Publications, 2017. p. 3-22.

Arnold M, De Vries E, Whiteman DC, Jemal A, Bray F, Parkin DM, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012. Int J Cancer. 2018;143(6):1305-14. https://doi.org/10.1002/ijc.31527 PMid:29659012 DOI: https://doi.org/10.1002/ijc.31527

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660

Fedorenko Z, Soumkina O, Gorokh Y, Goulak L, Koutsenko L. Cancer in Ukraine 2020-2021. Incidence, mortality, prevalence and other relevant statistics. In: Bulletin of the National Cancer Registry of Ukraine. Ukraine: National Cancer Registry of Ukraine; 2022. p. 86.

Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-update. Eur J Cancer. 2022;170:256-84. https://doi.org/10.1016/j.ejca.2022.04.018 PMid:35623961 DOI: https://doi.org/10.1016/j.ejca.2022.04.018

Michielin O, Van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: Under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1449-61. https://doi.org/10.1016/j.annonc.2020.07.005 PMid:32763452 DOI: https://doi.org/10.1016/j.annonc.2020.07.005

Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: Under the auspices of the ESMO guidelines committee. Ann Oncol. 2020;31(11):1435-48. https://doi.org/10.1016/j.annonc.2020.07.004 PMid:32763453 DOI: https://doi.org/10.1016/j.annonc.2020.07.004

Sekulovic LK, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, et al. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. Eur J Cancer. 2017;75:313-22. https://doi.org/10.1016/j.ejca.2017.01.012 PMid:28264791 DOI: https://doi.org/10.1016/j.ejca.2017.01.012

Carlino M, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002-14. https://doi.org/10.1016/S0140-6736(21)01206-X PMid:34509219 DOI: https://doi.org/10.1016/S0140-6736(21)01206-X

Hoffmann M, Hayoz S, Özdemir BC. Prescription patterns, recurrence, and toxicity rates of adjuvant treatment for stage III/IV melanoma-a real world single-center analysis. Biology (Basel). 2022;11(3):422. https://doi.org/10.3390/biology11030422 PMid:35336796 DOI: https://doi.org/10.3390/biology11030422

De Meza M, Ismail RK, Rauwerdink D, Van Not OJ, Van Breeschoten J, Blokx WA. Adjuvant treatment for melanoma in clinical practice-trial versus reality. Eur J Cancer. 2021;158:34- 245. https://doi.org/10.1016/j.ejca.2021.08.044 PMid:34600790 DOI: https://doi.org/10.1016/j.ejca.2021.08.044

Hu HP. Clinical predictors of survival in real-world practice in stage IV melanoma. Cancer Rep (Hoboken). 2023;6(2):e1691. https://doi.org/10.1002/cnr2.1691 PMid:36161287 DOI: https://doi.org/10.1002/cnr2.1691